$ALRZ Chardan Reiterates Buy on Aralez Pharmaceuticals Inc (ARLZ) Following FDA Approval
In a research report released Friday, Chardan Capital analyst Keay Nakae reiterated a Buy rating on shares of Aralez Pharmaceuticals Inc (NASDAQ:ARLZ) with a price target of $10
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.